|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
4.970 -0.020 (-0.401%) | 2024/12 - Final RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | 17,535,514 | 15,549,886 | 10,821,138 | 10,499,962 | 6,906,497 |
| Net Cash from / (used in) Investing Activities | (8,887,771) | (2,067,287) | (819,239) | (7,514,350) | (1,897,514) |
| Net Cash from / (used in) Financing Activities | (16,838,454) | (4,065,319) | (9,126,070) | 2,457,178 | (5,398,511) |
| Increase / (Decrease) in Cash & Cash Equivalents | (8,190,711) | 9,417,280 | 875,829 | 5,442,790 | (389,528) |
| Cash & Cash Equivalents at beginning of period | 24,650,670 | 15,223,726 | 14,315,973 | 9,182,812 | 10,560,630 |
| Effect of Foreign Exchange Rate Changes | (35,220) | 9,664 | 31,924 | (296,533) | (718,572) |
| Others | 0 | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | 16,424,739 | 24,650,670 | 15,223,726 | 14,329,070 | 9,452,531 |
| Remarks: | Real time quote last updated: 30/10/2025 09:31 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,077,282 |
| %Change | -20.252% |
| EPS / (LPS) | RMB 0.330 |
| NBV Per Share (¥) | RMB 7.953 |